

**PATENT****IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**In re Application of  
**WILS, ET AL**

Examiner: Ketter, J.

Serial No.: 09/153,838

Art Unit: 1636

Filed: September 15, 1998

Title: **PURIFICATION OF PLASMID DNA  
OF PHARMACEUTICAL QUALITY****TELEFAX CERTIFICATE**I hereby certify that this correspondence is being  
transmitted via facsimile 703-305-7939  
to the Commissioner for Patents, Washington, D.C.  
20231, on

July 9, 2001

Date of Transmission

Signature

*Boanidin***RESPONSE TO FINAL ACTION UNDER 37 CFR 1.116**Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the Final Office Action dated April 18, 2001, please amend the above-  
identified application as follows.**IN THE CLAIMS**

Please cancel claims 25 and 26 without prejudice.

**REMARKS**

The Examiner's indication that claims 1-22 are allowed is noted with appreciation.

In order to expedite the allowance of these claims, Applicants have cancelled claims 25 and  
26, thereby obviating the only rejection set forth in the Office Action.Accordingly, favorable reconsideration and prompt Notice of Allowance are earnestly  
solicited.

Respectfully submitted,

*Irving Newman*  
Irving Newman, Reg. No. 22,638  
Attorney for ApplicantAventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Telephone (908) 231-2785  
Telefax (908) 231-2626  
File: ST96016-USRECEIVED AS  
OFFICIAL  
TC 1600 FAX CENTER  
7/9/01PLEASE  
ENTER  
PH  
7/10/01#17/D  
MK  
7/10/01

**FAX TRANSMITTAL  
TO THE UNITED STATES PATENT OFFICE****Applicants Docket Number:**  
ST96016-US**Applicants:**  
Wills, et al**Serial No.**  
09/153,838**Filing Date:**  
September 15, 1998**Title of Invention:**  
**PURIFICATION OF PLASMID DNA OF PHARMACEUTICAL QUALITY****CERTIFICATE OF TRANSMISSION**

I hereby certify that this correspondence is being transmitted via  
facsimile to the Commissioner for Patents, Washington, D.C. 20231,  
at 703-305-7939, on  
Date of Deposit July 9, 2001  
Printed Name of Person Signing Certificate Bonnie Stein  
Signature *Bonnie Stein*

**Total Number of Pages Sent:** 2**Attorney:** Irving Newman**Group Art Unit:** 1636**Examiner:** J. Ketter**TO:** Commissioner for Patents  
Box  
Washington, D.C. 20231

Please acknowledge receipt of the below-listed documents for the above Application by returning this sheet,  
signed and dated, by return telefax to (908) 231-2626. If any fees are required, please charge our deposit  
account (18-1982) in the name of Aventis Pharmaceuticals Inc.

- |  |  |
|--|--|
| <input checked="" type="checkbox"/> Amendment, 37 CFR 1.116    | <input type="checkbox"/> Maintenance Fee Transmittal |
| <input type="checkbox"/> Assignment & Cover Sheet              | <input type="checkbox"/> Fee Transmittal             |
| <input type="checkbox"/> Charge deposit account, in duplicate  | <input type="checkbox"/> Petition under 37 CFR       |
| <input type="checkbox"/> Extension of Time Petition            | <input type="checkbox"/> Other                       |
| <input type="checkbox"/> Issue Fee Transmittal & Advance Order | <input type="checkbox"/> Other                       |

**Receipt Confirmed:**\_\_\_\_\_  
**Signed**\_\_\_\_\_  
**Dated**

Aventis Pharmaceuticals Inc., Route 202-206, P.O. Box 6800, Bridgewater, New Jersey 08807, U.S.A. [www.aventis.com](http://www.aventis.com)  
**NOTICE:** The documents accompanying this telecopy transmission are intended only for the use of the individual or entity named above. If you have received this  
telecopy in error, please immediately notify the sender by telephone to arrange for the return of the original documents.

Aventis Pharmaceuticals Inc. template (March 2001)